logo
HomeStocksMARKSANS

M

Marksans Pharma

MARKSANS Share PriceHealthcare

330.40

0.25 (0.08%)profit
as on 10 Sep 2026 at 03:29 PM
views52
portfolio2.4K
analyst100% Buy
Overview
Pros & Cons
News
History
Fundamentals
Investment Returns
Technicals
Financials
Balance Sheet
Cash Flow
Corporate Actions
Peers

Marksans Pharma Share Price Today

Today Marksans Pharma opened at 329.00 while its previous close was at 330.15. In todays trading session MARKSANS reached a high of 334.55 and low of 323.80. The average traded price for today is 330.42. The 50 DMA stands at 290.37 and 200 DMA is at 217.45. Looking at intraday trend, the stock is moving sideways.

Get 10+ Layouts, 100+ Indicators, Custom Timeframes & All Drawing Tools for FREE.

MARKSANS Stock Performance

Markets Today

High

334.55

Low

323.80

Open at

329.00

Prev Close

330.15

Volumes

12,95,256

Avg Price

330.42

Lower Circuit

264.35

Upper Circuit

396.45

Last Traded Details

Quantity

148

Time

15:29:59

Price Movement

323.80334.55
2.04%Loss
down side
up side
1.24%Profit

Historical Performance

3 M High

349.95

3 M Low

237.02

1 Yr High

349.95

1 Yr Low

155.00

3 Yr High

358.70

3 Yr Low

97.45

5 Yr High

358.70

5 Yr Low

38.60

1-Year Performance

155.00349.95
113.16%Loss
down side
up side
5.59%Profit

MARKSANS Pros and Cons

byfuzz AI

EBITDA margin expands from 16.1% in Q1 FY26 to 25.3% in Q1 FY27, showing strong pricing power.

Cash balance grows from ₹711 Cr in Q1 FY26 to ₹1,058 Cr in Q1 FY27, ensuring solid liquidity.

UK & Europe revenue climbs from ₹203.8 Cr in Q1 FY26 to ₹356 Cr in Q1 FY27, driving top-line growth.

Working capital cycle shortens from 159 days in Q1 FY26 to 132 days in Q1 FY27, improving cash conversion.

Net profit rises from ₹58.2 Cr in Q1 FY26 to ₹159.4 Cr in Q1 FY27, confirming consistent earnings delivery.

US & North America market share falls from 52.8% in Q1 FY26 to 44.9% in Q1 FY27, indicating competitive pressure.

US & North America revenue drops from ₹412.4 Cr in Q3 FY26 to ₹377.2 Cr in Q1 FY27, signaling regional softening.

Finance costs increase from ₹6.1 Cr in Q1 FY26 to ₹7.0 Cr in Q1 FY27, adding to operational expenses.

Rest of World revenue share declines from 3.7% in Q2 FY26 to 2.4% in Q1 FY27, reducing diversification benefits.

Tax expenses rise from ₹18.4 Cr in Q1 FY26 to ₹47.2 Cr in Q1 FY27, reflecting a higher effective tax burden.

fuzz Insights
Positive

Sales stalled but profits surged anyway.

Positive

Factory profits grew, but side income boosted the bottom line more.

Positive

One-time OTC sales flooded the cash register.

Positive

Faster cash collection follows the OTC sales surge.

Positive

Higher research spending didn't hurt profit margins.

Neutral

Europe is replacing the US as the top sales engine.

MARKSANS Analyst Rating

Buy

Analysts have suggested that investors can Buy this Stock

- By Refinitiv from 2 analysts

Buy

100%

Hold

0%

Sell

0%

Get forecast for Price, ROA & ROE based on analyst ratings.

Get Forecast

MARKSANS Share Price History

MARKSANS Fundamentals

Company Valuation

Market Cap (₹ Cr.)

14,977

PE Ratio

28.70

PB Ratio

4.95

Dividend Yield

0.27%

ROE

13.76%

ROCE

17.54%

Book Value (₹)

66.71

Face Value (₹)

1.00

Analyse MARKSANS with 12+ custom fundamentals and financial ratios.

Analyse Now

Share Holding Pattern

Held ByJun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
43.87%43.87%43.87%43.87%43.87%
Domestic Institutional Investors (DII)
5.50%5.28%5.91%6.57%6.19%
Foreign Institutional Investors (FII)
19.88%16.92%8.12%16.76%17.47%
Public Investors
26.75%29.53%28.98%28.33%28.05%
Government
0.00%0.00%0.00%0.00%0.00%

Promoters

Domestic Institutional Investors (DII)

Foreign Institutional Investors (FII)

Public Investors

Government

Marksans Pharma Return Calculator

You have invested
Investment Period

Current value of ₹1,00,000 invested 5 years ago, as on today

0

Gain

1,00,000 (371.66%)

Note: Past profits do not guarantee future returns.

MARKSANS Investment Returns

1 Week

1 Month

3 Months

6 Months

9 Months

Create Wealth in Longterm with Weekly and Monthly SIP in Stocks.

MARKSANS Technicals

Moving Averages

PeriodSimpleSignal
5-SMA332.01Bearish
10-SMA329.24Bullish
20-SMA326.47Bullish
50-SMA290.37Bullish
100-SMA257.70Bullish
200-SMA217.45Bullish

Technical Indicators

IndicatorValueAction
RSI(14)60.70Neutral
ATR(14)13.35Less Volatile
STOCH(9,6)63.87Neutral
STOCH RSI(14)29.42Neutral
MACD(12,26)-1.42Bearish
ADX(14)40.41Strong Trend

Summary of Technical Indicators for MARKSANS

Margin on MARKSANS

Order TypeMargin to PayLeverageQuantityTrade ValueMargin AmountActions

*Calculated on NSE. Applicable on all exchanges. Margins are subject to change from time to time or may be withdrawn under volatile market conditions. Intraday Orders are square-off automatically at 03:19 pm on NSE / BSE or on hitting 80% of margin utilisation (whichever earlier).

MARKSANS Financials Summary

View By:
Revenue
EBITDA
Net Profit
EPS
Revenue

In Crores

Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
626742775891866

MARKSANS Financials

View by

Income Statement

In Cr

Quarterly StatementJun 2025Sep 2025Dec 2025Mar 2026Jun 2026
626742775891866
Expenses520576594661628
106166181231238
Operating Profit100145161195213
Operating Profit Margin %16%20%21%23%25%
Other Income622203525
Interest66667
Depreciation2327242425
77133151200207
Tax %24%26%25%25%23%
Net Profit5899114149159
EPS12333

Balance Sheet

In Cr

Yearly Balance SheetMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
1,6402,1902,6813,2403,861
Fixed Assets4284867769821,044
Current Assets1,2011,6751,8632,2042,723
Capital Work in Progress31092759
Investments012710
Other Assets1,2091,6941,8692,2302,758
1,6402,1902,6813,2403,861
Current Liabilities356341390477527
Non Current Liabilities6184205273281
1,2231,7652,0862,4893,053
Reserve & Surplus1,0681,7002,0202,4222,978
Share Capital4145454545
Minority Interest2120212330

Cash Flow

In Cr

Yearly Cash FlowMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Activities99237230207458
Investing Activities-84-259-141-49-249
Financing Activities80198-69-65-71
Net Cash Flow941762193138

Corporate Actions

DateCorporate ActionInformation
20th Aug 2026, Thursday
DIVIDENDDividend
Final Dividend of ₹0.9/share
12th Aug 2026, Wednesday
QUARTERLY RESULT ANNOUNCEMENTStock Result
Q1 FY 26-27 Results
info
26th May 2026, Tuesday
QUARTERLY RESULT ANNOUNCEMENTStock Result
Q4 FY 26-27 Results
info
5th Feb 2026, Thursday
QUARTERLY RESULT ANNOUNCEMENTStock Result
Q3 FY 25-26 Results
info
13th Nov 2025, Thursday
QUARTERLY RESULT ANNOUNCEMENTStock Result
Q2 FY 25-26 Results
info

The above dates are ex-dates.

Check MARKSANS latest Company Filings, Investor Presentation & Conference Call details.

Read Now

MARKSANS Revenue Growth

All values are in Crores

Revenue

Profit

Loss

Financial YearRevenueRevenue GrowthNet ProfitProfit Growth
FY 2025-261,445
16.52% profit
301
59.71% profit
FY 2024-251,240
35.49% profit
188
40.76% profit
FY 2023-24915
27.9% profit
134
30.03% profit

NSE Indices Today

Index NamePrice

FAQs on MARKSANS

Marksans Pharma share price as of today is ₹ 330.40 as on 10 Sep 2026 at 03:29 PM.
The 52W high of Marksans Pharma is ₹ 349.95 and 52W low is ₹ 155.00 as of 10 Sep 2026 at 15:29.
The past returns of Marksans Pharma share are -
  • Past 1 year: 92.09%
  • Past 3 years: 213.03%
  • Past 5 years: 371.66%
The PE and PB ratio of Marksans Pharma stands at 28.70 and 4.95 respectively as on 10 Sep 2026 at 15:29.
The EPS of Marksans Pharma is 3.47 for the quarter ended Jun 2026 and 9.22 for the financial year 2025-26.
The shareholding pattern of Marksans Pharma is as follows:
  • DIIs - 6.19%
  • FII - 17.47%
  • Promoters - 43.87%
  • Public Investors 28.05%
  • Goverenment - 0.00%
Yes, you can buy shares of Marksans Pharma online by opening Demat account with Dhan.
If you are a Dhan user already, you can buy Marksans Pharma stocks from Dhan Trading App or Web Trading Platform. If you are new to Dhan follow the below steps:
  1. Download the Dhan App to Open a Demat Account
  2. Navigate to the “Money Tab”
  3. Add money to your account
  4. Search for Marksans Pharma share
  5. Tap on “Buy”
With Dhan you can start a daily, weekly or monthly SIP in Marksans Pharma.
You can easily buy the shares of Marksans Pharma even after the markets are closed using the After Market Order feature on Dhan Trading App.


Explore  |  Sitemap

*All securities mentioned on this website are exemplary and not recommendatory.

*Current prices on the website are delayed by 15 mins, login to check live prices.

We are bullish on India, we are bullish on India's prospects to be one of the largest economies in the world. We believe that the stock market provides a unique opportunity for all of India's traders and investors to participate in the growth story of the country.

Yet, most investing & trading platforms in India have remained more or less the same over the past decade. Times have changed and retail traders and investors have become smarter about managing their trades and money. Modern traders & investors require an online trading platform that helps them keep up with the technological advancements of our time.

That's why we're building Dhan - to help you trade, to help you invest, and to help you participate in India's growth stock via the stock market with awesome features and an incredible experience.

©2021-2026 Raise Securities Private Limited (formerly Moneylicious Securities Private Limited). All rights reserved. CIN: U74999MH2012PTC433549 Raise Securities is part of Raise Financial Services and works closely with Raise Partners across services.

SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016 | SEBI Research Analyst Registration No: INH000023357
Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320
Registered & Corporate Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai – 400104, Customer Care: 9987761000.


For any query / feedback / clarifications, email at help@dhan.co.

In case of grievances for any of the services rendered by Raise Securities Private Limited, please write to grievance@dhan.co (for NSE, BSE and MCX) or grievancedp@dhan.co (for Depository Participant). Please ensure that you carefully read the Risk Disclosure Document as prescribed by SEBI, our Terms of Use and Privacy Policy. Compliance Officer: Mr. Manish Garg and Mobile: 8655740961 Email: complianceofficer@dhan.co To lodge your complaints using SEBI SCORES, click here.


Disclaimer: All communications with the client via chat, phone, or email are for support purposes only. Any commitments or statements made by the agent (human or virtual) shall not be binding on the company.


DHAN is a brand owned by Raise Securities Private Limited. All DHAN clients are registered under Raise Securities Private Limited. Clients are advised to refer to our company as Raise Securities Private Limited when communicating with regulatory authorities.


Procedure to file a complaint on SEBI SCORES/SMART ODR Portal: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances. You may refer the website https://scores.sebi.gov.in/ for more information. You may also download the SEBI Scores app to log a complaint Android: https://play.google.com store apps sebiscores iOS: https://apps.apple.com app sebiscores.


Disclaimer: Investment in the securities market are subject to market risks, read all the related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit


Attention investors:

  1. Stock brokers can accept securities as margins from clients only by way of pledge in the depository system w.e.f September 01, 2020.
  2. Update your e-mail and phone number with your stock broker / depository participant and receive OTP directly from depository on your e-mail and/or mobile number to create pledge.
  3. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month.

Note: As a policy we do not give stock tips or recommendations and have not authorized anyone to give this on behalf of us. If you know anyone claiming to be a part of Dhan / / Raise or our associate companies or partners and offering such services, please report us on help@dhan.co. Important Information for Investors: To prevent unauthorized transactions in your trading / demat account, do not share your account details, credentials or any personal details with anyone. Keep your mobile number updated with your Stock Broker, Depository Participant and ensure that the same is registered with Stock Exchanges, Depository and KRAs. You will receive alerts and information on your registered mobile number / email for debit and other important transactions in your demat account directly from CDSL / Exchange on the same day. KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Stock Broker, DP, Mutual Fund, etc.), you need not undergo the same process again when you approach another intermediary. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. This is issued in the interest of investors.


Investors should be cautious on unsolicited emails and SMS advising to buy, sell or hold securities and trade only on the basis of informed decision. Investors are advised to invest after conducting appropriate analysis of respective companies and not to blindly follow unfounded rumours, tips etc. Further, you are also requested to share your knowledge or evidence of systemic wrongdoing, potential frauds or unethical behaviour through the anonymous portal facility provided on BSE & NSE website. Issued in the interest of the investors.


Raise Securities Private Limited also known as Dhan is only an order collection platform that collects orders on behalf of clients and places them on BSE StarMF for execution. Client expressly agrees that Dhan is not liable or responsible and does not represent or warrant any damages regarding non- execution of orders or any incorrect execution of orders with regard to the funds chosen by the client or due to, but not being limited to, any link/system failure, delay in transfer of the funds on account of any unforeseen circumstances/issues in the banking system/payment aggregators or any other problems that may result in a delay in crediting the funds into the BSE Star MF's bank account. Raise Securities Private Limited (Dhan) does not engage in proprietary trading on its own account.


Mutual fund investments are subject to market risks, read all scheme related documents carefully before investing. Dhan is not a distributor or agent of any mutual fund. Mutual Funds are not exchange-traded products. Any related disputes will not have access to the Exchange-investor redressal forum or arbitration mechanism. For other disclaimers please refer https://dhan.co/advertisement-disclaimer/


Download client registration documents (Rights & Obligations, Risk Disclosure Document, Do's & Don'ts) in vernacular language: BSE | NSE | MCX


Kindly, read the Advisory Guidelines of BSE | NSE | MCX for investors as prescribed by the exchange with reference to their circular dated 27th August, 2021 regarding investor awareness and safeguarding client's assets


Important Links: SEBI | BSE | NSE | MCX | CDSL | SCORES | ODR Portal | Investor Charter for Stock Brokers | Investor Charter for DP | Investor Charter for Research Analyst | UCC Advisory | e-Voting for Shareholders | NCL Client Collateral details | MCXCCL Client Collateral details

Important Information: Terms of Usage | Disclaimers | Privacy Policy | Grievances | Grievances RA | Risk Management Policy | Risk Disclosure | Advertisement Disclaimer | Referral Terms & Conditions | Saarthi 2.0 Mobile App for Investors | Master Circular for Online Dispute Resolution